Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies

v3.2.0.727
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2015
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

4) Summary of Significant Accounting Policies

 

Principles of Consolidation

 

The condensed consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly-owned subsidiary PBI BioSeq, Inc. All intercompany accounts and transactions have been eliminated in consolidation.

 

Use of Estimates

 

To prepare our condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in projecting future cash flows to quantify deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded and warrant derivative liability. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used.

 

Concentrations

 

Credit Risk

 

Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories.

 

The following table illustrates the level of concentration as a percentage of total revenues during the three months and six months ended June 30, 2015 and 2014.

 

    For the Three Months Ended  
    June 30,  
    2015     2014  
Top Five Customers     65 %     64 %
Federal Agencies     27 %     3 %

 

    For the Six Months Ended  
    June 30,  
      2015       2014  
Top Five Customers     49 %     42 %
Federal Agencies     22 %     2 %

 

The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of June 30, 2015 and December 31, 2014:

 

    June 30, 2015     December 31, 2014  
Top Five Customers     70 %     86 %
Federal Agencies     1 %     9 %

 

Product Supply

 

BIT Group, Inc. has been our sole contract manufacturer for our PCT NEP3229 and NEP2320 instrumentation.

  

Computation of Loss per Share

 

Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive to our net loss.

 

The following table illustrates our computation of loss per share for the three months and six months ended June 30, 2015 and 2014:

  

    For the Three Months Ended     For the Six Months Ended  
    June 30,     June 30,  
    2015     2014     2015     2014  
Numerator:                                
Net loss   $ (1,386,241 )   $ (603,187 )   $ (2,772,232 )   $ (2,362,842 )
Accrued dividend for Preferred Stock     (6,811 )     (9,606 )     (23,479 )     (54,593 )
Deemed dividend on Series K Convertible Preferred Stock     -       (107,996 )     -       (1,388,062 )
Net loss applicable to common shareholders   $ (1,393,052 )   $ (720,789 )   $ (2,795,711 )   $ (3,805,497 )
                                 
Denominator for basic and diluted loss per share:                                
Weighted average common stock shares outstanding     19,682,632       13,567,472       19,247,895       12,848,751  
                                 
Loss per common share - basic and diluted   $ (0.07 )   $ (0.05 )   $ (0.14 )   $ (0.30 )

 

The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H Convertible Preferred Stock, Series J Convertible Preferred Stock and Series K Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms.

 

    For the Six Months Ended  
    June 30,  
    2015     2014  
Stock options     3,251,250       1,585,750  
Convertible debt     14,420,144       917,860  
Common stock warrants     19,182,201       17,757,044  
Convertible preferred stock:                
Series D Convertible Preferred Stock     750,000       750,000  
Series G Convertible Preferred Stock     865,700       865,700  
Series H Convertible Preferred Stock     1,000,000       1,000,000  
Series H2 Convertible Preferred Stock     2,100,000       -  
Series J Convertible Preferred Stock     3,546,000       4,995,000  
Series K Convertible Preferred Stock     11,416,000       11,463,000  
      56,531,295       39,334,354  

 

Accounting for Stock-Based Compensation Expense

 

We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant.

  

Determining Fair Value of Stock Option Grants

 

Valuation and Amortization Method - The fair value of each option award is estimated on the date of grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period.

 

Expected Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical exercise data on which to base an estimate of expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted.

 

Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award.

 

Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term.

 

Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of 5% for awards granted based on historical experience and future expectations of options vesting. The Company used this historical rate as our assumption in calculating future stock-based compensation expense.

 

The Company recognized stock-based compensation expense of $55,616 and $21,488 for the three months ended June 30, 2015 and 2014, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Condensed Consolidated Statements of Operations:

 

    For the Three Months Ended
June 30,
 
    2015     2014  
Research and development   $ 11,523     $ 10,301  
Selling and marketing     7,099       5,914  
General and administrative     36,994       5,273  
Total stock-based compensation expense   $ 55,616     $ 21,488  

 

We recognized stock-based compensation expense of $110,506 and $40,384 for the six months ended June 30, 2015 and 2014, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Condensed Consolidated Statements of Operations:

 

    For the Six Months Ended
June 30,
 
    2015     2014  
Research and development   $ 22,865     $ 17,854  
Selling and marketing     14,075       11,905  
General and administrative     73,566       10,625  
Total stock-based compensation expense   $ 110,506     $ 40,384  

 

Fair Value of Financial Instruments

 

Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their fair value. Long-term liabilities are primarily related to liabilities transferred under contractual arrangements with carrying values that approximate fair value.

 

Fair Value Measurements

 

The Company follows the guidance of FASB ASC Topic 820, “Fair Value Measurements and Disclosures” (“ASC 820”) as it related to all financial assets and financial liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis.

 

The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions.

  

Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that it does not have any financial assets measured at fair value and that its financial liabilities are currently all classified within Level 3 in the fair value hierarchy. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management.

 

The following tables set forth the Company’s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2015.

 

          Fair value measurements at June 30, 2015 using:  
             
    June 30, 2015    

Quoted prices in
active markets

(Level 1)

    Significant other
observable inputs
(Level 2)
    Significant
unobservable inputs
(Level 3)
 
Series D Preferred Stock Purchase Warrants   $ 124,643       -       -     $ 124,643  
Conversion Option Liabilities     1,731,650       -       -       1,731,650  
Total Derivatives   $ 1,856,293       -       -     $ 1,856,293  

 

    January 1, 2015     Issuance
fair value
    Change in
fair value
    Gain on
extinguishment
of embedded
derivative
liabilities
    June 30, 2015  
Series D Preferred Stock Purchase Warrants   $159,875     -     $ (35,232 )   -     $124,643  
Conversion Option Liabilities     590,341       2,032,181       (42,799 )     (848,073 )     1,731,650  
Total Derivatives   $ 750,216     $ 2,032,181     $ (78,031 )   $ (848,073 )   $ 1,856,293  

 

The assumptions for the binomial pricing model are represented in the table below for the warrants issued in the Series D private placement reflected on a per share common stock equivalent basis.

 

Assumptions   November 10, 2011     Warrants revalued at
December 31, 2014
    Warrants revalued at
June 30, 2015
 
Expected life (in months)     60.0       22.0       16.0  
Expected volatility     104.5 %     116.0 %     116.1 %
Risk-free interest rate     0.875 %     0.58 %     0.48 %
Exercise price   $ 0.81     $ 0.25     $ 0.25  
Fair value per warrant   $ 0.54     $ 0.15     $ 0.12  

 

The assumptions for the binomial pricing model are represented in the table below for the conversion options reflected on a per share common stock equivalent basis.

 

Assumptions   At Issuance fair value   At Settlement fair value   Conversion options
revalued at
June 30, 2015
Expected life (in months)   6-24   0-6   2-21
Expected volatility   104.2-153.8%   0.8-142.2%   88.6-130.6%
Risk-free interest rate   0.05-0.99%   0.01-0.18%   0.01-0.54%
Exercise price   $0.10-$0.35   $0.10-$0.16   $0.11-$0.25
Fair value per conversion option   $0.09-$0.28   $0.10-$0.26   $0.08-$0.16